argenx
Global immunology company developing antibody-based therapies for severe autoimmune diseases.
About
Technology stack
detected 2026-06-21No comments yet. Be the first to share your take.
What does argenx do?
Argenx is a global, commercial-stage biopharmaceutical company focused on developing and delivering transformative therapies for patients with severe autoimmune diseases. They leverage their expertise in immunology and antibody engineering to create a pipeline of novel antibody-based medicines, with a flagship product, Vyvgart (efgartigimod alfa), approved for conditions like generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
How much funding has argenx raised?
argenx has raised a total of $51M in funding. The most recent round on record is Series B.
Where is argenx headquartered?
argenx is headquartered in Amsterdam, Netherlands.
When was argenx founded?
argenx was founded in 2008.
What industry does argenx operate in?
argenx operates in BiTech, Biopharmaceuticals, Immunology, Drug Discovery, Antibody Therapeutics, Autoimmune Diseases.